drugset / Trial / NCT05826990

A Study to Investigate PK, Safety, Tolerability of Cefepime-enmetazobactam in Pediatric Participants With cUTI

NCT05826990

Phase 2 Unknown 40 enrolled Allecra Linical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase 2 study is part of regulatory commitments in the United States (PSP) and Europe (PIP) to evaluate cefepime-enmetazobactam in paediatric participants with cUTI to support extension of the indication for cefepime-enmetazobactam to children with cUTI.

Timeline

Start
2023-09-11
Primary completion
2025-09-30
Completion
2026-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Cefepime Small molecule Intravenous
Subject enmetazobactam Small molecule Intravenous